GSK, CureVac Team up to Develop Vaccine Targeting COVID-19 Variants

CureVac is also collaborating with Bayer to speed up development and production of that vaccine.

RIO DE JANEIRO, BRAZIL - Britain’s GlaxoSmithKline (GSK) and German biotech firm CureVac have teamed up in a 150 million euro deal to develop a COVID-19 vaccine next year that could target several variants with one shot.

New, more contagious mutations of COVID-19 have emerged in Britain, South Africa and Brazil and while existing vaccines appear to offer some protection against them, there are fears further changes in the virus could lessen the efficacy of current shots.

For GSK, the world’s largest vaccine maker by sales, the deal marks a fresh attempt to play a major role . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?